Toll-like receptor agonists: a patent review (2011 – 2013)

Self-Adjuvanting Polymer–Peptide Conjugates As Therapeutic Vaccine Candidates against Cervical Cancer

(2013) Tzu-Yu Liu et al.   BIOMACROMOLECULES

Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours

(2013) M Millward et al.   BRITISH JOURNAL OF CANCER

Targeting Toll-like receptors with small molecule agents

(2013) Xiaohui Wang et al.   CHEMICAL SOCIETY REVIEWS

Modern Subunit Vaccines: Development, Components, and Research Opportunities

(2013) Peter Michael Moyle et al.   ChemMedChem

The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma

(2013) Kai-Michael Beeh et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Structural Reorganization of the Toll-Like Receptor 8 Dimer Induced by Agonistic Ligands

(2013) H. Tanji et al.   SCIENCE

Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies

(2012) Brenda J. Weigel et al.   AMERICAN JOURNAL OF HEMATOLOGY

Structural basis of innate immune recognition of viral RNA

(2012) Ian C. Berke et al.   CELLULAR MICROBIOLOGY

Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer

(2012) S. Adams et al.   CLINICAL CANCER RESEARCH

New developments in Toll-like receptor targeted therapeutics

(2012) Dympna J Connolly et al.   CURRENT OPINION IN PHARMACOLOGY

Advances in Peptide-based Human Papillomavirus Therapeutic Vaccines

(2012) Tzu-Yu Liu et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Topical Treatment with the Toll-like Receptor Agonist DIMS0150 Has Potential for Lasting Relief of Symptoms in Patients with Chronic Active Ulcerative Colitis by Restoring Glucocorticoid Sensitivity

(2012) Eugen Musch et al.   INFLAMMATORY BOWEL DISEASES

Safety and Immunogenicity of Vaccination With MART-1 (26–35, 27L), gp100 (209–217, 210M), and Tyrosinase (368–376, 370D) In Adjuvant With PF-3512676 and GM-CSF In Metastatic Melanoma

(2012) Ahmad A. Tarhini et al.   JOURNAL OF IMMUNOTHERAPY

Design of Fully Synthetic, Self-Adjuvanting Vaccine Incorporating the Tumor-Associated Carbohydrate Tn Antigen and Lipoamino Acid-Based Toll-like Receptor 2 Ligand

(2012) Abu-Baker M. Abdel-Aal et al.   JOURNAL OF MEDICINAL CHEMISTRY

Results of a Phase 1 Dose Escalation Study of Intravesical TMX-101 in Patients with Nonmuscle Invasive Bladder Cancer

(2012) Johannes Falke et al.   JOURNAL OF UROLOGY

Liposome-based delivery system for vaccine candidates: constructing an effective formulation

(2012) Ashwini Kumar Giddam et al.   Nanomedicine

Genetic variation in Toll-like receptors and disease susceptibility

(2012) Mihai G Netea et al.   NATURE IMMUNOLOGY

Synthetic Toll Like Receptor-4 (TLR-4) Agonist Peptides as a Novel Class of Adjuvants

(2012) Arulkumaran Shanmugam et al.   PLoS One

A Double-Blind, Placebo-Controlled, Randomized, Clinical Trial of the TLR-3 Agonist Rintatolimod in Severe Cases of Chronic Fatigue Syndrome

(2012) David R. Strayer et al.   PLoS One

Peptide-Based Subunit Vaccine against Hookworm Infection

(2012) Mariusz Skwarczynski et al.   PLoS One

Structural basis of species-specific endotoxin sensing by innate immune receptor TLR4/MD-2

(2012) U. Ohto et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis

(2012) Lennart Greiff et al.   RESPIRATORY RESEARCH

Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine

(2012) Benjamin P. Sablan et al.   VACCINE

TLR9-adjuvanted pneumococcal conjugate vaccine induces antibody-independent memory responses in HIV-infected adults

(2012) Rasmus Offersen et al.   Human Vaccines & Immunotherapeutics

Toll-Like Receptor 8 Ligands Activate a Vitamin D Mediated Autophagic Response that Inhibits Human Immunodeficiency Virus Type 1

(2012) Grant R. Campbell et al.   PLoS Pathogens

Peptide-Based Subunit Nanovaccines

(2012) Mariusz Skwarczynski et al.   Current Drug Delivery

Trial Watch

(2012) Lorenzo Galluzzi et al.   OncoImmunology

Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV

(2011) J. F. Bergmann et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer

(2011) C. Manegold et al.   ANNALS OF ONCOLOGY

Simple synthetic toll-like receptor 2 ligands

(2011) Abu-Baker M. Abdel-Aal et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study

(2011) L. Klimek et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Phase I Study Utilizing a Novel Antigen-Presenting Cell-Targeted Vaccine with Toll-like Receptor Stimulation to Induce Immunity to Self-antigens in Cancer Patients

(2011) M. A. Morse et al.   CLINICAL CANCER RESEARCH

The Innate Immune Response, Clinical Outcomes, and Ex Vivo HCV Antiviral Efficacy of a TLR7 Agonist (PF-4878691)

(2011) M D Fidock et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Toll-like receptors

(2011) Eva Marie Y. Moresco et al.   CURRENT BIOLOGY

Toll-like receptor modulators: a patent review (2006 – 2010)

(2011) Shaherin Basith et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and Immunity

(2011) Taro Kawai et al.   IMMUNITY

Innate immunity to intracellular pathogens: macrophage receptors and responses to microbial entry

(2011) Annette Plüddemann et al.   IMMUNOLOGICAL REVIEWS

Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

(2011) Vera Hirsh et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia

(2011) Clive S. Zent et al.   LEUKEMIA & LYMPHOMA

Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers

(2011) Dianna Rynkiewicz et al.   VACCINE

Structural requirement for the agonist activity of the TLR2 ligand Pam2Cys

(2010) Weiguang Zeng et al.   AMINO ACIDS

Polyacrylate Dendrimer Nanoparticles: A Self-Adjuvanting Vaccine Delivery System

(2010) Mariusz Skwarczynski et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Pattern Recognition Receptors and Inflammation

(2010) Osamu Takeuchi et al.   CELL

Sublingual Allergen-Specific Immunotherapy Adjuvanted with Monophosphoryl Lipid A: A Phase I/IIa Study

(2010) Oliver Pfaar et al.   INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY

Cutting Edge: Type I IFN Reverses Human Th2 Commitment and Stability by Suppressing GATA3

(2010) J. P. Huber et al.   JOURNAL OF IMMUNOLOGY

Memory and Effector CD8 T-cell Responses After Nanoparticle Vaccination of Melanoma Patients

(2010) Daniel E. Speiser et al.   JOURNAL OF IMMUNOTHERAPY

Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2

(2010) Tomoko Hayashi et al.   MELANOMA RESEARCH

Self-adjuvanting polyacrylic nanoparticulate delivery system for group A streptococcus (GAS) vaccine

(2010) Mehfuz Zaman et al.   Nanomedicine-Nanotechnology Biology and Medicine

The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors

(2010) Taro Kawai et al.   NATURE IMMUNOLOGY

Targeting Toll-like receptors: emerging therapeutics?

(2010) Elizabeth J. Hennessy et al.   NATURE REVIEWS DRUG DISCOVERY

Regulation of Adaptive Immunity by the Innate Immune System

(2010) A. Iwasaki et al.   SCIENCE

Structure–activity relationship of lipopeptide Group A streptococcus (GAS) vaccine candidates on toll-like receptor 2

(2010) Mehfuz Zaman et al.   VACCINE

Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists

(2009) Jörg Vollmer et al.   ADVANCED DRUG DELIVERY REVIEWS

Drugs targeting toll-like receptors

(2009) Jayalakshmi Krishnan et al.   ARCHIVES OF PHARMACAL RESEARCH

Lipid Core Peptide System for Gene, Drug, and Vaccine Delivery

(2009) Wei Zhong et al.   AUSTRALIAN JOURNAL OF CHEMISTRY

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

(2009) Christopher G. Azzoli et al.   JOURNAL OF CLINICAL ONCOLOGY

The Effects of Cytokines on Suppression of Lymphocyte Proliferation by Dexamethasone

(2009) T. J. Creed et al.   JOURNAL OF IMMUNOLOGY

The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complex

(2009) Beom Seok Park et al.   NATURE

Toll-like receptor 2 dependent immunogenicity of glycoconjugate vaccines containing chemically derived zwitterionic polysaccharides

(2009) S. Gallorini et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Innate immune sensing and activation of cell surface Toll-like receptors

(2009) Richard I. Tapping   SEMINARS IN IMMUNOLOGY

In vivo and in vitro adjuvant activities of the B subunit of Type IIb heat-labile enterotoxin (LT-IIb-B5) from Escherichia coli

(2009) Shuang Liang et al.   VACCINE

Self-Adjuvanting Lipopeptide Vaccines

(2008) Peter Moyle et al.   CURRENT MEDICINAL CHEMISTRY

Functional diversification of the toll-like receptor gene family

(2008) Austin L. Hughes et al.   IMMUNOGENETICS

TLR7 Agonist 852A Inhibition of Tumor Cell Proliferation Is Dependent on Plasmacytoid Dendritic Cells and Type I IFN

(2008) Jon R. Inglefield et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

Toll-like receptor 9 (TLR9) agonists in the treatment of cancer

(2008) A M Krieg   ONCOGENE

Toll-like receptors and immune regulation: implications for cancer therapy

(2008) R-F Wang et al.   ONCOGENE

TLR7 and TLR8 as targets in cancer therapy

(2008) M P Schön et al.   ONCOGENE

Structural Basis of Toll-Like Receptor 3 Signaling with Double-Stranded RNA

(2008) L. Liu et al.   SCIENCE

The PorB porin from commensal Neisseria lactamica induces Th1 and Th2 immune responses to ovalbumin in mice and is a potential immune adjuvant

(2008) Xiuping Liu et al.   VACCINE